Our partnerships incorporate our creative approach by leveraging each partner’s capabilities to ensure a win-win.
We are seeking a variety of dynamic partnerships, including:
OUT-LICENSING
- Global commercial partnerships for our branded
ADHD portfolio - Opportunities to license our drug formulation technologies to create mutual value with our partners
IN-LICENSING
- Branded portfolio expansion opportunities leveraging our commercial presence in pediatrics and CNS
- Opportunities to in-license, acquire, and/or codevelop generic products
We’re proud of our effective and fulfilling partnerships:
Connect and see what we can build together
This form is not intended for use in reporting adverse events related to Tris Pharma products. You may report such events by calling 1-732-940-0358 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch, where healthcare professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit MedWatch or call 1-800-FDA-1088.
Our patient-inspired technology has enabled many successful partnerships
What can LiquiXR® technology offer your drug candidates?